REporting recommendations for tumour MARKer prognostic studies (REMARK)

By Adrian L. Harris. British Journal of Cancer, 2005

777 citations recorded by the source corpus.

One of the key ways to translate new basic discoveries into clinical relevance is the analysis of gene expression in tumour samples, relating this to various outcomes. These may include relapse-free survival and overall survival, sites of metastasis and, of course, differential expression in tumour vs normal is important to describe. The above are prognostic factors, but use of markers to predict which patients will benefit from increasingly complex and expensive therapies is potentially of high utility and a logical follow on, once patients with poor prognosis are selected. To achieve the goal of individualised medicine, with the selection of correct therapy for the molecular pathways in the tumour, this approach is needed.

Subfields: Cancer Research, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/90adf0d9588bb4ec40fd5295c8054a63fea00dd3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. De Bock
2. H. Nijman
3. Marloes J. M. Gooden
4. N. Leffers
5. T. Daemen

In Radiology, Nuclear Medicine and Imaging

1. De Bock
2. H. Nijman
3. Marloes J. M. Gooden
4. N. Leffers
5. T. Daemen

Citations in the corpus

• An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics (2018, methodology): “Similar to Consolidated Standards of Reporting Trials (CONSORT) guidelines for reporting randomized clinical trials (Schulz et al., 2010), REMARK seeks to improve the transparency and reproducibility of prognostic marker studies.”
• Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. (2007, neutral): “For authors of observational studies that specifically address diagnostic tests, tumour markers and genetic associations, STARD [13], REMARK [14], and STREGA [15] recommendations may be particularly useful.”
• Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. (2012, methodology): “Results are reported according to REMARK (Reporting Recommendations for Tumour Marker Prognostic Studies) guidelines.(16) Table 1.”
• Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration (2007, neutral): “McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. (2005) REporting recommendations for tumour MARKer prognostic studies (REMARK).”
• The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis (2011, methodology): “They proposed guidelines for the reporting of prognostic marker studies, to encourage transparent reporting and to assist the reader in judging study quality (McShane et al , 2005).”
• Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts (2016, positive): “The REMARK criteria were followed, wherever possible, throughout this study (14).”